may be pertinent to the pathogenesis, phenomenology, and possible treatment of several mental disorders. In keeping with this view, the targeting of interleukin-6 with the human monoclonal antibody sirukumab may represent a possible treatment and disease modification approach, for adults with brain-based disorders (e.g., major depressive disorder). A PubMed/Medline database search was performed using the following search terms: sirukumab; anti-IL-6; IL-6; major depressive disorder; inflammation. A systematic review was conducted of both preclinical and clinical trials reporting on the pharmacology of sirukumab or investigating the efficacy of targeting IL-6 signaling. Overall, sirukumab has been reported to be a safe and well-tolerated agent, capable of modulating the immune response in healthy populations as well as in subjects with inflammatory disorders (e.g., rheumatoid arthritis). Sirukumab's effects on cytokine networks as part of the innate immune system provide a coherent rationale for possible application in neuropsychiatric disorders with possible benefits across several domains of the biobehavioral Research Domain Criteria matrix (e.g., general cognitive processes, positive valence systems). Amongst individuals with complex brain-based disorders (e.g., mood disorders), the dimensions/domains most likely to benefit with sirukumab are negative valence disturbances (e.g., anxiety, Notwithstanding the evolutionary benefits of the inflammatory response in the presence of physical threat, its overactivity in response to everyday social stressors is thought to result in depressive symptomology [11] . A detailed review of the role of inflammation in depression, including the neurochemical mechanisms by which the immune system affects mood and behavior, is outlined from an evolutionary perspective elsewhere [12] . Components of the innate immune response include the action of several cytokines, chemokines, cellular adhesion molecules, and acute phase reactants. Of the foregoing categories of inflammatory protein systems, alteration in interleukin-6 (IL-6) levels has been identified as one of the most reproducible abnormalities in MDD [13] .
INTRODUCTION
In addition to being an intrinsic abnormality in adults with MDD, for many individuals with MDD, alterations in the immune inflammatory system are a secondary phenomenon to either the behavioral disturbances observed in depression (e.g., sleep disturbance), comorbidity (e.g., obesity), and/or iatrogenic effects (e.g., weight-gain-promoting psychotropic agents) [11] . Notwithstanding the potential confounding effects of other contributing factors, alterations in immune inflammatory systems in adults with MDD are also reported in individuals without comorbidities and who are medication-naïve [14] . Moreover, the observation of alterations in messenger RNA transcripts in unaffected relatives of probands with mood disorders provides further evidence that disturbances in inflammatory system are a trait abnormality in adults with MDD [15] .
Interleukin-6
Interleukin-6 is a pleiotropic cytokine synthesized and released in response to inflammatory signaling, with both pro-and anti-inflammatory properties. As a pro-inflammatory cytokine, IL-6 is a potent transcriptional stimulus for the production of acute-phase proteins [e.g., C-reactive protein (CRP)] [16, 17] , recruitment of leukocytes, and augmentation of the production of other pro-inflammatory chemokines [18] . IL-6 is also reported to play a role in anti-inflammatory processes, including the activation and enhanced production of anti-inflammatory molecules (e.g., macrophage type 2, IL-1 receptor antagonist) [19, 20] .
The production and method of signaling of IL-6 has been reviewed in detail elsewhere [21] . The rationale for targeting IL-6 is further augmented by the established interconnectedness of IL-6, as well as other cytokine systems, in effector systems relevant to the pathoetiology and phenomenology of MDD. For example, it is well established that inflammatory cytokines modulate amino acid synthesis, release, and availability (e.g., glutamate), as well as playing a critical role in cellular respiration in oxidative processes. Moreover, cytokine systems implicated as abnormal in MDD are in interplay with the hypothalamic-pituitary-adrenal (HPA) axis and are significantly modulated by circadian rhythms, as well as gut enterotype. Taken together, the foregoing set of effector systems (e.g., glutamate dysregulation, oxidative stress, glucocorticoid signaling alterations, circadian dysrhythmicity, and gut dysbiosis) are all implicated as pathoetiologically relevant in MDD [22, 23] .
Preclinical and clinical evidence also indicates that IL-6 is associated with deficits in cognitive function [23] . Moreover suggesting that IL-6 may be a relevant proximate mediator of disease processes in MDD [27] .
Convergent lines of evidence indicate that both peripheral and central IL-6 levels are also significantly elevated in adults exhibiting self-harm (i.e., suicide attempt) [8, 28] . For example, Lindqvist et al. [8] reported that CSF IL-6 levels were significantly higher in individuals with MDD (mean = 3.76 pg/mL) and in individuals who attempted violent suicide (mean = 5.25 pg/mL) when compared to healthy controls (mean = 0.64 pg/mL). In a separate study, Janelidze et al. [28] The average maximum serum concentration (C max ) value has been reported to increase in a dose-dependent manner in healthy subjects (i.e., 7.9-248.8 lg/mL for doses of 0.3-10 mg/ kg [43] reported that subjects with baseline serum high-sensitivity (hs) CRP levels greater than 5 mg/L were significantly more likely to respond to the tumor necrosis factor (TNF)
antagonist infliximab [43] , whereas subjects with baseline hs-CRP levels no greater than 5 mg/L were more likely to respond to placebo.
The foregoing study result, in need of replication, provides empirical evidence that a specific anti-inflammatory biologic is differentially effective in a subset of adults with MDD stratified by phenomenological and biological characteristics.
Patient-Reported Outcomes
Sirukumab has been demonstrated to rapidly (Fig. 1) .
The foregoing hypothesis is being empirically tested in an ongoing randomized, placebo-controlled, double-blind phase II study that aims to test the efficacy and safety of sirukumab as an adjunctive treatment to monoaminergic antidepressant therapy in adults with MDD (NCT02473289). In addition to mitigating conventional depression outcome measures (e.g., reduction in overall depression symptom severity), the totality of evidence would suggest that an inflammatory-based approach may be particularly effective for the dimension/domain of general cognitive disturbances, as well as positive and negative emotional valence abnormalities [23] .
A strategic approach that would need to be kept in mind when evaluating sirukumab is replicated evidence indicating that subpopulations of individuals with MDD may be more likely to benefit from an intervention that targets, directly or indirectly, the inflammatory system. For example, evidence indicates that individuals with higher baseline levels of inflammatory markers would be preferentially responsive to infliximab, omega-3 fatty acids, exercise, and ketamine.
We would propose that the study of sirukumab in adults with MDD should stratify patients on the basis of elevated inflammatory markers or signature, e.g., CRP. Moreover, sirukumab is an expensive biologic, notwithstanding the availability of an increasing number of ''biosimilars''. We do not envisage in the short term that biologics will be a feasible treatment 
